BioArctic

Report Publication Announcement • Aug 14, 2018

Press release

Invitation to presentation of BioArctic's Interim Report for the period January – June 2018 on August 23, 2018

Stockholm, Sweden, August 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January – June 2018 on Thursday, August 23, 2018 at 08:00 a.m. CET.

BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on August 23, at 09:30 – 10:30 a.m. CET.

Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the period January – June 2018 followed by a Q&A-session.

To attend, please dial-in at one of the numbers below from: Sweden: + 46 8 566 426 63 Denmark: + 45 354 455 75 Germany: + 49 692 222 290 46 The Netherlands: + 31 207 168 416 Switzerland: + 41 225 675 548 UK: + 44 203 008 9814 US: + 1 855 831 5946

Webcast: https://tv.streamfabriken.com/bioarctic-q2-2018

The webcast will afterwards also be available on demand at BioArctic's corporate website www.bioarctic.com, Investors, Financial presentations.

For more information, please contact:

Christina Astrén, IR & Communications Director Telephone: + 46 70 835 43 36 E-mail: [christina.astren@bioarctic.se](javascript:DeCryptX()

About BioArctic

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant marketand out-licensing potential. BioArctic's B-share is listed on Nasdaq Stockholm Mid Cap (STO: BIOA B). www.bioarctic.com

This information was submitted for publication at 08:00 a.m. CET on August 14, 2018.